Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults-Reference-Cited by-同舟云学术

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults

Published:2024-01-03 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Levy Matthew E¹^ORCID,Burrows Evanette¹,Chilunda Vanessa¹,Pawloski Pamala A²,Heaton Phillip R³,Grzymski Joseph⁴⁵,Goldman Jason D⁶⁷⁸,McEwen Lisa M¹,Wyman Dana¹,Dei Rossi Andrew¹,Dai Hang¹,Isaksson Magnus¹,Washington Nicole L¹,Basler Tracy¹,Tsan Kevin¹,Nguyen Jason¹,Ramirez Jimmy¹,Sandoval Efren¹,Lee William¹,Lu James¹,Luo Shishi¹

Affiliation:

1. Helix , San Mateo, California , USA

2. HealthPartners Institute , Minneapolis, Minnesota , USA

3. Department of Pathology and Laboratory Medicine, HealthPartners , Bloomington, Minnesota , USA

4. Department of Internal Medicine, University of Nevada Reno, School of Medicine , Reno, Nevada , USA

5. Renown Health , Reno, Nevada , USA

6. Providence St. Joseph Health System , Renton, Washington , USA

7. Swedish Center for Research and Innovation, Swedish Medical Center , Seattle, Washington , USA

8. Division of Infectious Disease, University of Washington , Seattle, Washington , USA

Abstract

Abstract Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022–June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Funder

Helix

Desert Research Institute

University of Nevada

Reno School of Medicine

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad796/55566592/ciad796.pdf

Reference12 articles.

1. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs;Saravolatz;Clin Infect Dis,2023

2. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition;Xie;JAMA Intern Med,2023

3. Nirmatrelvir or molnupiravir use and severe outcomes from Omicron infections;Lin;JAMA Netw Open,2023

4. Early remdesivir to prevent progression to severe COVID-19 in outpatients;Gottlieb;N Engl J Med,2022